Bris­tol-My­er's Op­di­vo teams up with In­fin­i­ty's last hope

Bris­tol-My­er’s Op­di­vo will team up with In­fin­i­ty Phar­ma­ceu­ti­cals’ last hope IPI-549 in a Phase I. In­fin­i­ty will run the check­point in­hibitor and PI3K-gam­ma in­hibitor …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.